01
BPC-157 — what the rodent literature can and cannot tell us
A close read of the 2024-2026 published rodent-model evidence for BPC-157, the gaps in human translation, and what an honest dose-finding protocol would look like in a human pilot.
Library · Lab Notes
Lab Notes.
One compound per quarter. Drafted by the formulation team, sourced from primary literature, signed by the named author, reviewed by two team members who didn't draft it. Bibliographies, dosing- curve interpretations, the unflattering data competitors omit.
First edition · Q3 2026
We don't publish until the named author is on the masthead.
Per our editorial standards, every Lab Note carries the formulation chemist's byline, credentials, and signature. The chemist joins publicly in Q2 2026 (see the About page); the first Lab Note follows one quarter later. Inner Circle members will receive each piece 14 days before public release.
Join the Inner Circle waitlist →On the docket
The first four essays.
The quarterly cadence runs through 2026 and 2027. Essay topics are chosen by the formulation team based on (a) compounds in the Hero-20 catalog, (b) gaps in the public Canadian literature, and (c) reader questions submitted via editorial@novopharma.cc.
02
GLP-1 in 2026 — semaglutide, tirzepatide, retatrutide compared
Receptor profile differences, head-to-head trial readouts where available, and what the published phase-3 data actually permits us to claim about each agent's metabolic effects.
03
How we read a Janoshik COA
Field by field — what HPLC purity %, the technician signature, the method appendix, and the chromatogram trace each tell you. Why a >99% claim without the trace is unverifiable.
04
Cold-chain failure modes — what actually happens to a peptide above 8°C
The published peptide-stability literature on freeze-thaw cycles, ambient excursion times, and aqueous stability windows. Why our cold-pack mailer matters more than most vendors admit.